Validation of an abbreviated quality of life scale for schizophrenia

European Neuropsychopharmacology

Volumn 23, Issue 9, 2013, Pages 1072-1077

  Fervaha, Gagan ^a,b   Remington, Gary ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apathy; Functioning; QLS; Quality of life; Rating scale; Schizophrenia

Indexed keywords

ADULT; AGED; ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEASUREMENT ACCURACY; MULTIPLE REGRESSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEMI STRUCTURED INTERVIEW; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

APATHY; FUNCTIONING; QLS; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84884203035     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.11.009     Document Type: Article

References (25)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Publishing, Inc., Washington, DC.
3. Bilker W.B., Brensinger C., Kurtz M.M., Kohler C., Gur R.C., Siegel S.J., Gur R.E. Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology 2003, 28:773-777.
4. Evensen J., Rossberg J.I., Barder H., Haahr U., Hegelstad W., Joa I., Johannessen J.O., Larsen T.K., Melle I., Opjordsmoen S., Rund B.R., Simonsen E., Sundet K., Vaglum P., Friis S., McGlashan T. Apathy in first episode psychosis patients: a ten year longitudinal follow-up study. Schizophr. Res. 2012, 136:19-24.
5. Faerden A., Friis S., Agartz I., Barrett E.A., Nesvag R., Finset A., Melle I. Apathy and functioning in first-episode psychosis. Psychiatr. Serv. 2009, 60:1495-1503.
6. First M.B. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version 1997, American Psychiatric Publishing Inc, Washington, DC.
7. Fisher M., Holland C., Merzenich M.M., Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry 2009, 166:805-811.
8. Grant P.M., Beck A.T. Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. Schizophr. Bull. 2009, 35:798-806.
9. Grant P.M., Huh G.A., Perivoliotis D., Stolar N.M., Beck A.T. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch. Gen. Psychiatry 2012, 69:121-127.
10. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
11. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
13. Keefe R.S., Mohs R.C., Bilder R.M., Harvey P.D., Green M.F., Meltzer H.Y., Gold J.M., Sano M. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr. Bull. 2003, 29:45-55.
14. Konstantakopoulos G., Ploumpidis D., Oulis P., Patrikelis P., Soumani A., Papadimitriou G.N., Politis A.M. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr. Res. 2011, 133:193-198.
15. Leifker F.R., Patterson T.L., Heaton R.K., Harvey P.D. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull. 2011, 37:334-343.
16. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
17. McEvoy J.P., Apperson L.J., Appelbaum P.S., Ortlip P., Brecosky J., Hammill K., Geller J.L., Roth L. Insight in schizophrenia. Its relationship to acute psychopathology. J. Nerv. Ment. Disord. 1989, 177:43-47.
18. Mohamed S., Rosenheck R., Swartz M., Stroup S., Lieberman J.A., Keefe R.S. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am. J. Psychiatry 2008, 165:978-987.
19. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 2012, 137:147-150.
20. Remington G., Foussias G., Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
21. Ritsner M., Kurs R., Ratner Y., Gibel A. Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Res. 2005, 135:65-75.
22. Sabbag S., Twamley E.W., Vella L., Heaton R.K., Patterson T.L., Harvey P.D. Predictors of the accuracy of self assessment of everyday functioning in people with schizophrenia. Schizophr. Res. 2012, 137:190-195.
23. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29:15-31.
24. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., Reimherr F., McGee M.F., Keefe R.S., McEvoy J.P., Hsiao J.K., Lieberman J.A. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164:428-436.
25. Tungstrom S., Soderberg P., Armelius B.A. Relationship between the Global Assessment of Functioning and other DSM axes in routine clinical work. Psychiatr. Serv. 2005, 56:439-443.